EGFR and neoplasm: To understand and to overcome AR to EGFR-TKIs, researchers have explored resistance mechanisms by analyzing tumor specimens obtained from patients who developed AR to an EGFR-TKI [9,10,11] or by analyzing cell lines that acquired resistance to an EGFR-TKI in vitro by chronic exposure to the drug [10,11,12].